, Volume 13, Issue 4, pp 317–326 | Cite as

The impact of EPLINα (Epithelial protein lost in neoplasm) on endothelial cells, angiogenesis and tumorigenesis

  • Andrew J. SandersEmail author
  • Lin Ye
  • Malcolm D. Mason
  • Wen G. Jiang
Original Paper



EPLIN (epithelial protein lost in neoplasm) is a cytoskeletal associated protein involved in the regulation of actin dynamics and subsequently in cell motility. EPLIN expression is frequently reduced in a variety of cancer cells and tissues and this loss may account for increased invasive traits in cancer cells. The current study aimed to assess the role of EPLIN in endothelial cells and the angiogenic process.


EPLINα expression was enhanced in HECV endothelial cells through transfection with a pEF6 expression plasmid containing the full coding sequence of EPLINα. The impact of EPLINα on HECV cells was then assessed using a range of in vitro and in vivo models.


Transfection and over-expression of HECV cells with EPLINα expression plasmid resulted in a significant reduction in cell-matrix adhesion (P = 0.003), the rate of migration (P = 0.009) and tubule formation (P = 0.007) and also enhanced paxillin staining compared to transfection controls. Additionally, MDA-MB-231 breast cancer cells co-injected with HECVEPLIN exp cells developed at a slower rate than those co-injected with HECVpEF6 cells (day 26, P = 0.05; day 33, P = 0.065, overall deviation over time P < 0.001). Treatment of HECVEPLIN exp cells with ERK inhibitor could rescue HECV cells from the inhibitory effect of EPLINα over-expression on tubule formation, returning these cells to control levels.


EPLINα over-expression can regulate HECV cell motility, matrix adhesion and tubule formation in vitro and slow in vivo tumour formation, suggesting an anti-angiogenic role for EPLINα. Extracellular signal-regulated kinase (ERK) also appears to be linked to the ability of EPLINα to inhibit tubule formation in vitro.


EPLIN Endothelial cells ERK Tubule formation Tumour angiogenesis 



The authors are grateful to Cancer Research Wales for their support and funding this study.


  1. 1.
    Chang DD, Park NH, Denny CT, Nelson SF, Pe M (1998) Characterization of transformation related genes in oral cancer cells. Oncogene 16(15):1921–1930CrossRefPubMedGoogle Scholar
  2. 2.
    Maul RS, Chang DD (1999) EPLIN, epithelail protein lost in neoplasm. Oncogene 18:7838–7841CrossRefPubMedGoogle Scholar
  3. 3.
    Chen S, Maul RS, Kim HR, Chang DD (2000) Characterization of the human EPLIN (Epithelial Protein Lost in Neoplasm) gene reveals distinct promoters for the two EPLIN isoforms. Gene 248:69–76CrossRefPubMedGoogle Scholar
  4. 4.
    Jiang WG, Martin TA, Lewis-Russell JM, Douglas-Jones A, Ye L, Mansel RE (2008) Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Mol Cancer 7:71–80CrossRefPubMedGoogle Scholar
  5. 5.
    Song Y, Maul RS, Gerbin CS, Chang DD (2002) Inhibition of anchorage-independent growth of transformed NIH3T3 cells by epithelial protein lost in neoplasm (EPLIN) requires localization of EPLIN to actin cytoskeleton. Mol Biol Cell 13:1408–1416CrossRefPubMedGoogle Scholar
  6. 6.
    Maul RS, Song Y, Amann KJ, Gerbin SC, Pollard TD, Chang DD (2003) EPLIN regulates actin dynamics by cross-linking and stabilizing filaments. J Cell Biol 160:399–407CrossRefPubMedGoogle Scholar
  7. 7.
    Abe K, Takeichi M (2008) EPLIN mediates linkage of the cadherin-catenin complex to F-actin and stabilizes the circumferential actin belt. PNAS 105:13–19CrossRefPubMedGoogle Scholar
  8. 8.
    Chircop M, Oakes V, Graham ME, Ma MP, Smith CM, Robinson PJ, Khanna KK (2009) The actin-binding and bundling protein, EPLIN, is required for cytokinesis. Cell Cycle 8(5):757–764PubMedGoogle Scholar
  9. 9.
    Parr C, Sanders AJ, Davies G, Martin T, Lane J, Mason MD, Mansel RE, Jiang WG (2007) Matriptase-2 inhibits breast growth and invasion and correlates with favorable prognosis for breast cancer patients. Clin Cancer Res 13:3568–3576CrossRefPubMedGoogle Scholar
  10. 10.
    Parr C, Watkins G, Mansel RE, Jiang WG (2004) The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 10:202–211CrossRefPubMedGoogle Scholar
  11. 11.
    Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Scott C, Puntis MCA (1995) Inhibition of invasion and motility of human colon cancer cells by gamma linolenic acid. Br J Cancer 71:744–752PubMedGoogle Scholar
  12. 12.
    Jiang WG, Hiscox SE, Parr C, Martin TA, Matsumoto K, Nakamura T, Mansel RE (1999) Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Cancer Res 5:3695–3703Google Scholar
  13. 13.
    Grant DS, Tashiro K, Segui-Real B, Yamada Y, Martin GR, Kleinman HK (1989) Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 58:933–943CrossRefPubMedGoogle Scholar
  14. 14.
    Maul RS, Gerbin CS, Chang DD (2001) Characterization of mouse epithelial protein lost in neoplasm (EPLIN) and comparison of mammalian and zebrafish EPLIN. Gene 262:155–160CrossRefPubMedGoogle Scholar
  15. 15.
    Han MY, Kosako H, Watanabe T, Hattori S (2007) Extracellular signal-regulated kinase/mitogen-activated protein kinase regulates actin organization and cell motility by phosphorylating the actin cross-linking protein EPLIN. Mol Cell Biol 27(23):8190–8204CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Andrew J. Sanders
    • 1
    Email author
  • Lin Ye
    • 1
  • Malcolm D. Mason
    • 2
  • Wen G. Jiang
    • 1
  1. 1.Metastasis and Angiogenesis Research GroupCardiff University School of MedicineCardiffUK
  2. 2.Department of Clinical OncologyCardiff University School of MedicineCardiffUK

Personalised recommendations